en · de · es
sr9009-notes.peptides7501.com › Topic › Background And Mechanism — Practical Notes

Background And Mechanism — Practical Notes

By Editorial Desk · published 2026-02-09 · last reviewed 2026-02-23 · Topic

REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-02-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Background and Pharmacological Mechanism

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Analytical Detection and Stability

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Related pages on this site

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Reference notes

== Screening == Because it can be difficult to measure weight-for-height Z scores (WHZ) frequently, screening is performed by physical exam, with careful examination of the child's feet to detect the presence of bilateral pitting edema. Screening for edema is essential for the diagnosis of kwashiorkor, since nearly two-thirds of kwashiorkor cases do not have evidence of acute wasting (i.e. mid-upper arm circumference (MUAC) < 125 mm, or WHZ < -2) when diagnosed with kwashiorkor.

== External links == "Tiratricol ( Code - C66605 )". EVS Explore. "Tiratricol Sodium ( Code - C218928 )". EVS Explore. Clinical trial number NCT05579327 for "Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) (ReTRIACt)" at ClinicalTrials.gov Clinical trial number NCT02060474 for "Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients" at ClinicalTrials.gov

=== First attempts, halting follow-up === When jamming was first attempted by the Germans it was in a much more clever fashion than had been anticipated. The observation that the transmissions of the individual stations were spread out in time, in order to avoid mutual interference, was exploited. A system was designed to send back spurious broadband pulses on a chosen CH station's time slot. The CH operator could avoid this signal simply by changing their time slot slightly, so the jamming was not received. This caused the station's signals to start overlapping another's time slot, so that station would attempt the same cure, affecting another station in the network, and so forth. A series of such jammers were set up in France starting in July 1940, and soon concentrated into a single station in Calais that affected CH for some time. However, the timing of these attempts was extremely ill-considered. The British quickly developed operational methods to counteract this jamming, and these had effectively eliminated the effect of the jamming by the opening of the Battle of Britain on 10 July. The Germans were well on their way to develop more sophisticated jamming systems, but these were not ready for operation until September. This meant that the CH system was able to operate unmolested throughout the Battle, and led to its well-publicized successes. By the opening of the Battle in July the German Luftwaffe operational units were well aware of CH, and had been informed by the DVL that they could not expect to remain undetected, even in clouds.

Sources: en.wikipedia.org

Reference notes

Thirty years later, this work inspired, independently, two research groups to adopt the H-phosphonate chemistry to the solid-phase synthesis using nucleoside H-phosphonate monoesters 7 as building blocks and pivaloyl chloride, 2,4,6-triisopropylbenzenesulfonyl chloride (TPS-Cl), and other compounds as activators. The practical implementation of H-phosphonate method resulted in a very short and simple synthetic cycle consisting of only two steps, detritylation and coupling (Scheme 2). Oxidation of internucleosidic H-phosphonate diester linkages in 8 to phosphodiester linkages in 9 with a solution of iodine in aqueous pyridine is carried out at the end of the chain assembly rather than as a step in the synthetic cycle. If desired, the oxidation may be carried out under anhydrous conditions. Alternatively, 8 can be converted to phosphorothioate 10 or phosphoroselenoate 11 (X = Se), or oxidized by CCl4 in the presence of primary or secondary amines to phosphoramidate analogs 12. The method is very convenient in that various types of phosphate modifications (phosphate/phosphorothioate/phosphoramidate) may be introduced to the same oligonucleotide for modulation of its properties. Most often, H-phosphonate building blocks are protected at the 5'-hydroxy group and at the amino group of nucleic bases A, C, and G in the same manner as phosphoramidite building blocks (see below). However, protection at the amino group is not mandatory.

=== Use by right-to-die societies === High toxicity and relatively easy availability made propoxyphene a drug of choice for right-to-die societies. It is listed in Dr. Philip Nitschke's The Peaceful Pill Handbook and Dr. Pieter Admiraal's Guide to a Humane Self-Chosen Death. "With the withdrawal of the barbiturate sleeping tablets from the medical prescribing list, propoxyphene has become the most common doctor-prescribed medication used by seriously ill people to end their lives."

== Adverse effects == Products containing lisdexamphetamine have a comparable drug safety profile to those containing amphetamine. The major side effects of lisdexamphetamine in short-term clinical trials (≥5% incidence) have included decreased appetite, insomnia, dry mouth, weight loss, irritability, upper abdominal pain, nausea, vomiting, diarrhea, constipation, increased heart rate, anxiety, dizziness, and feeling jittery. Rates of side effects may vary in adults, adolescents, and children. Rare but serious side effects of lisdexamphetamine may include mania, sudden cardiac death in those with underlying heart problems, stimulant psychosis, and serotonin syndrome.

Sources: en.wikipedia.org

Reference notes

== General scheme == The HSQC experiment is a highly sensitive 2D-NMR experiment and was first described in a 1H–15N system, but is also applicable to other nuclei such as 1H–13C and 1H–31P. The basic scheme of this experiment involves the transfer of magnetization on the proton to the second nucleus, which may be 15N, 13C, or 31P, via an INEPT (insensitive nuclei enhanced by polarization transfer) step. After a time delay (t1), the magnetization is transferred back to the proton via a retro-INEPT step and the signal is then recorded. In HSQC, a series of experiments is recorded where the time delay t1 is incremented. The 1H signal is detected in the directly measured dimension in each experiment, while the chemical shift of 15N or 13C is recorded in the indirect dimension which is formed from the series of experiments.

Paper chromatography is an analytical method used to separate colored chemicals or substances. It can also be used for colorless chemicals that can be located by a stain or other visualisation method after separation. It is now primarily used as a teaching tool, having been replaced in the laboratory by other chromatography methods such as thin-layer chromatography (TLC). This analytic method has three components, a mobile phase, stationary phase and a support medium (the paper). The mobile phase is generally a non-polar organic solvent in which the sample is dissolved. The stationary phase consists of (polar) water molecules that were incorporated into the paper when it was manufactured. The mobile phase travels up the stationary phase by capillary action, carrying the sample with it. The difference between TLC and paper chromatography is that the stationary phase in TLC is a layer of adsorbent (usually silica gel, or aluminium oxide), and the stationary phase in paper chromatography is less absorbent paper. A paper chromatography variant, two-dimensional chromatography, involves using two solvents and rotating the paper 90° in between. This is useful for separating complex mixtures of compounds having similar polarity, for example, amino acids.

Results suggest that triptans, ditans, and gepants are all associated with reduced pain at 2 hours, with triptans being the most successful. Gepants were the least likely to cause adverse events, with some triptans having a higher risk than gepants, and ditans having the highest risk among all treatments.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

Network